Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts

Class I drug recalls - the high-risk category

Class I is the FDA's most serious recall category: a reasonable probability that using the product will cause serious health consequences or death. It is a small share of all recalls, but the one to check first if a medication you take appears here.

1,750 recalls, newest first.

Class I · High risk

Hyoscyamine Sulfate

Failed Content Uniformity Specifications: resulting in both superpotent and subpotent tablets.

Terminated Wrong potency / content Virtus Pharmaceuticals Opco II L NDC 76439-308-10 D-0214-2017
Class I · High risk

Hyoscyamine Sulfate

Failed Content Uniformity Specifications: resulting in both superpotent and subpotent tablets.

Terminated Wrong potency / content Virtus Pharmaceuticals Opco II L NDC 76439-307-10 D-0213-2017
Class I · High risk

Hyoscyamine Sulfate

Failed Content Uniformity Specifications: resulting in both superpotent and subpotent tablets.

Terminated Wrong potency / content Virtus Pharmaceuticals Opco II L NDC 76439-309-10 D-0212-2017
Class I · High risk

Comfort Shield

Microbial Contamination of Non-Sterile Products: contamination with the bacteria, Burkholderia cepacia.

Terminated Microbial contamination Sage Products LLC NDC 53462-915-50 D-0229-2017
Class I · High risk

Cetylev (acetylcysteine)

Defective Container: Incomplete seal on blister packaging, leading to tablet swelling and enlarging due to effervescence process beginning as oxygen and moisture enter the blister packaging.

Terminated Packaging defect Arbor Pharmaceuticals Inc. NDC 24338-700-10 D-0105-2017
Class I · High risk

Diocto Liquid

Microbial contamination of Non-Sterile Products; positive findings of Burkholderia cepacia

Terminated Microbial contamination The Harvard Drug Group NDC 0536-0590-85 D-0022-2017
Class I · High risk

Super Samurai-X

Marketed without an approved NDA/ANDA: FDA sample analyses revealed the presence of undeclared sildenafil and/or its analogs in products marketed as dietary supplements

Terminated Chemical / undeclared SOS Telecom Inc. D-0104-2017
Class I · High risk

Ginseng Power-X

Marketed without an approved NDA/ANDA: FDA sample analyses revealed the presence of undeclared sildenafil and/or its analogs in products marketed as dietary supplements

Terminated Chemical / undeclared SOS Telecom Inc. D-0103-2017
Class I · High risk

Ninja-X

Marketed without an approved NDA/ANDA: FDA sample analyses revealed the presence of undeclared sildenafil and/or its analogs in products marketed as dietary supplements

Terminated Chemical / undeclared SOS Telecom Inc. D-0102-2017
Class I · High risk

Tiger-X

Marketed without an approved NDA/ANDA: FDA sample analyses revealed the presence of undeclared sildenafil and/or its analogs in products marketed as dietary supplements

Terminated Chemical / undeclared SOS Telecom Inc. D-0101-2017
Class I · High risk

PHENYLephrine 1 mg/10 mL

Labeling: Label Error on Declared Strength. Product has correct label on the syringe and the case but some units are incorrectly labeled as .4 mg/10 mL (40 mcg/ml) on the light protective overwrap of each syringe.

Terminated Labeling / mix-up QuVa Pharma, Inc. D-1066-2016
Class I · High risk

Cap-Biotin 100 Mg

Labeling: Label Mix-Up: Products labeled Biotin 100 mg found to contain 4-aminopyridine

Terminated Labeling / mix-up Reliable Rexall-A Compounding Pharmacy D-1068-2016
Class I · High risk

Morphine Sulfate 0.5 mg/mL

Super-Potent Drug: Out of specification for potency results (high) were obtained for one lot of morphine sulfate Inj.

Terminated Wrong potency / content Pharmakon Pharmaceuticals NDC 45183-0322-78 D-0871-2016

Recalls by year